Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 284 results
Press release cover image

Sep 2, 2026

Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases

— Leveraging Cutting-Edge Causal AI-Based Digital Twins —Aitia’s Gemini Digital Twin (GDT) platform enables the inference of causal relationships to identify novel drug targets, which is not possible with conventional correlation-based AI. Each GDT is a virtual patient model that reflects the disease characteristics of real patients.GDTs are built by Aitia’s causal AI-based REFS™ technology, which is expected to be highly compatible with the discovery of novel therapeutic targets for neurologica
Press release cover image

Sep 1, 2026

DnaK Therapeutics & GATC Health Forge A Partnership To Evaluate, Accelerate & Prioritize Cancer Drug Candidates Using AI Platform

TAMPA, Fla. and IRVINE, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- DnaK Therapeutics and GATC Health Corp jointly announced today a collaboration to use GATC’s proprietary artificial intelligence platform to evaluate and prioritize 16 innovative, potential cancer drug candidates. By applying GATC’s predictive AI platform early in the drug-development process, DnaK will be able to prioritize the most promising molecules for preclinical studies, obviating months off traditional experimental time
Press release cover image

Aug 28, 2026

Clicklinks | Sanyou Bio Launches Clicklinks, an AI-Driven Innovation Hub for Original Drug Discovery

SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Sanyou Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Sanyou Bio"), today announced the official launch of Clicklinks, an AI-STAL and SAI-DA powered collaborative network designed to support original drug discovery and preclinical development.Positioned as an Innovation Hub for Original Drug Discovery, Clicklinks brings together industry partners across the biopharmaceutical value chain to enable more efficient, integrated, and scalable R&D.
Molecular model kit illustrating protein-drug interactions in a lab setting.

Aug 28, 2026

KAIST unveils 'K-Fold,' a sovereign biotech AI model it says is 25 times faster than Google's

KAIST has introduced K-Fold, a groundbreaking biotech AI model that significantly accelerates the prediction of protein-drug binding, positioning itself as a robust alternative to established models like Google DeepMind’s AlphaFold3.Developed by a consortium at KAIST, K-Fold leverages advanced AI technology to predict not only the three-dimensional structures of proteins but also their interactions with drug candidates. This capability is crucial in drug development, enabling faster identificati
Press release cover image

Aug 27, 2026

Ainnocence Shows AINN-P1 Protein Foundation Model Improves Antibody-Antigen Affinity Ranking by 28% - From Sequence Alone

Ainnocence’s foundation model trained from scratch, requiring no structure, no multiple sequence alignment, no fine-tuning, training in hours rather than weeks.Ainnocence Inc.,an AI-driven pharmaceutical & material IP-generating platform company,today released research showing that representations learned by its AINN-P1protein foundation model substantially improve a core task in antibodyengineering: ranking candidate antibody-antigen pairs by binding affinity.Using AINN-P1 as a frozen encod
A flat illustration of a human cell with a CRISPR tool, symbolizing gene editing.

Aug 25, 2026

New CRISPR Screening Service, Calla Lily Joins Wellcome Leap’s Program, Baylor College to Establish Xenoliver Transplant Center

Recent developments in the life sciences sector highlight significant advancements in technology and collaborations aimed at enhancing drug discovery and addressing critical health challenges.Bit.bio has introduced the ioScreen platform, a CRISPR screening service designed to facilitate human cell-based drug discovery. This platform allows researchers to manipulate gene activity, thereby deepening the understanding of disease mechanisms. Utilizing bit.bio's ioCells and other cell types, ioScreen
Press release cover image

Aug 24, 2026

Ainnocence Reports 91.4% Program Success Rate Across 58 Antibody Affinity Maturation Campaigns, Opens 28-Program Biologics Pipeline to Licensing

Structure-free AI platform delivers picomolar leads while cutting wet-lab validation to 20-50 samples per roundAinnocence Inc., an AI-driven pharmaceutical & material IP-generatingplatform company, today reported performance results from 75 completed proteindesign programs and announced that it is seeking licensing and partneringagreements for 28 antibody, bispecific and ADC programs that have generatedpositive preclinical data across oncology, immunology and metabolicindications. Across 58a
A minimalist illustration of a pill and a molecule representing AI in drug discovery.

Aug 22, 2026

Domestic pharma industry deploying AI for drug discovery: MoS Health Anupriya Patel

At the IIMA Healthcare Summit, Minister of State for Health Anupriya Patel emphasized the transformative potential of artificial intelligence (AI) in India's pharmaceutical sector, aiming to transition from being known as the "pharmacy of the world" to becoming a "laboratory of the world."Patel highlighted the increasing integration of AI by domestic drug manufacturers to expedite the drug discovery process, indicating a shift in the industry’s focus. This technology not only aims to enhance ear
Press release cover image

Aug 21, 2026

The9's Investee Nanyang Biologics (NYB) Advancing toward Nasdaq Listing after RFAI Cleared Vote at Shareholders Extraordinary General Meeting

Milestone Marks Further Progress in The9's Strategic Investment in AI-Driven Drug Discovery; The9 Expects to Hold Approximately 15% to 16% of the Combined, Nasdaq-Listed CompanySHANGHAI, Aug. 21, 2026 /PRNewswire/ -- The9 Limited (Nasdaq: NCTY) ("The9" or the "Company"), a global, diversified high-tech company, today announced that Nanyang Biologics Pte. Ltd. ("NYB"), a Singapore-based, AI-driven drug discovery company in which The9 holds a strategic equity stake, has taken a significant step to
A protein binder on a lab bench with scientific equipment in the background.

Aug 20, 2026

Claude Science outperforms experts in protein binder task

Anthropic's AI model, Claude Science, has demonstrated remarkable capabilities in protein design, outperforming human experts in a recent challenge.In a recent evaluation, Claude Science successfully designed protein binders for 14 out of 15 specified targets, achieving superior results compared to previous design competitions. The AI’s performance was validated through collaboration with Adaptyc Bio and Twist Bioscience, where it utilized advanced models to achieve hit rates significantly above
Press release cover image

Aug 20, 2026

Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery

SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Bristol Myers Squibb to advance the discovery of therapeutic antibodies using artificial intelligence.Under the collaboration, Bristol Myers Squibb will leverage Chai’s advanced AI models and platform capabilities, including its leading molecular folding and design models, to support the discovery of antibody candidates across its portfolio and
Press release cover image

Aug 20, 2026

Matwings Demonstrates Closed-Loop Protein AI Through Four AI-Wet Lab Cycles and 222 Protein Variants

The GenSci148 program illustrates a shift from one-time mutation prediction to iterative protein engineering under real drug-development constraintsSHANGHAI, Aug. 20, 2026 /PRNewswire/ -- Shanghai Matwings Technology Co., Ltd. ("Matwings") today announced that GenSci148 Injection, an investigational ophthalmic biologic developed by Changchun GeneScience Pharmaceutical Co., Ltd. ("GenSci"), has received clinical trial clearance in China for neovascular age-related macular degeneration (nAMD), dia